OCUP — Ocuphire Pharma Income Statement
0.000.00%
Last trade - 00:00
- $51.59m
- $4.42m
- $19.05m
- 32
- 35
- 37
- 27
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.589 | 39.9 | 19 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 11.2 | 16.3 | 23.3 | 21.6 | 29.6 |
Operating Profit | -11.2 | -16.3 | -22.7 | 18.2 | -10.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.64 | -24.6 | -56.7 | 18.2 | -9.97 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.64 | -24.6 | -56.7 | 17.9 | -9.99 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.64 | -24.6 | -56.7 | 17.9 | -9.99 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.64 | -24.6 | -56.7 | 17.9 | -9.99 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -8.71 | -3.82 | -3.62 | 0.868 | -0.402 |